CN106008340B - 稠环衍生物、其制备方法、中间体、药物组合物及应用 - Google Patents

稠环衍生物、其制备方法、中间体、药物组合物及应用 Download PDF

Info

Publication number
CN106008340B
CN106008340B CN201610071297.XA CN201610071297A CN106008340B CN 106008340 B CN106008340 B CN 106008340B CN 201610071297 A CN201610071297 A CN 201610071297A CN 106008340 B CN106008340 B CN 106008340B
Authority
CN
China
Prior art keywords
compound
mmol
added
alkyl
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201610071297.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN106008340A (zh
Inventor
许祖盛
张农
孙庆瑞
吴添智
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Yingli Pharmaceutical Co Ltd
Original Assignee
Shanghai Yingli Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Yingli Pharmaceutical Co Ltd filed Critical Shanghai Yingli Pharmaceutical Co Ltd
Priority to CN201810188236.0A priority Critical patent/CN108516958B/zh
Priority to CN201810188235.6A priority patent/CN108299425B/zh
Priority to TW105109178A priority patent/TWI675026B/zh
Priority to TW106139600A priority patent/TWI666201B/zh
Publication of CN106008340A publication Critical patent/CN106008340A/zh
Application granted granted Critical
Publication of CN106008340B publication Critical patent/CN106008340B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/36—Benzo-cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201610071297.XA 2015-03-24 2016-02-01 稠环衍生物、其制备方法、中间体、药物组合物及应用 Active CN106008340B (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201810188236.0A CN108516958B (zh) 2015-03-24 2016-02-01 稠环衍生物、其制备方法、中间体、药物组合物及应用
CN201810188235.6A CN108299425B (zh) 2015-03-24 2016-02-01 稠环衍生物、其制备方法、中间体、药物组合物及应用
TW105109178A TWI675026B (zh) 2015-03-24 2016-03-24 稠環衍生物、其製備方法、中間體、藥物組合物及應用
TW106139600A TWI666201B (zh) 2015-03-24 2016-03-24 稠環衍生物、其製備方法、中間體、藥物組合物及應用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2015101318285 2015-03-24
CN201510131828 2015-03-24

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201810188236.0A Division CN108516958B (zh) 2015-03-24 2016-02-01 稠环衍生物、其制备方法、中间体、药物组合物及应用
CN201810188235.6A Division CN108299425B (zh) 2015-03-24 2016-02-01 稠环衍生物、其制备方法、中间体、药物组合物及应用

Publications (2)

Publication Number Publication Date
CN106008340A CN106008340A (zh) 2016-10-12
CN106008340B true CN106008340B (zh) 2020-03-17

Family

ID=56977003

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201810188236.0A Active CN108516958B (zh) 2015-03-24 2016-02-01 稠环衍生物、其制备方法、中间体、药物组合物及应用
CN201810188235.6A Active CN108299425B (zh) 2015-03-24 2016-02-01 稠环衍生物、其制备方法、中间体、药物组合物及应用
CN201610071297.XA Active CN106008340B (zh) 2015-03-24 2016-02-01 稠环衍生物、其制备方法、中间体、药物组合物及应用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201810188236.0A Active CN108516958B (zh) 2015-03-24 2016-02-01 稠环衍生物、其制备方法、中间体、药物组合物及应用
CN201810188235.6A Active CN108299425B (zh) 2015-03-24 2016-02-01 稠环衍生物、其制备方法、中间体、药物组合物及应用

Country Status (14)

Country Link
US (2) US10100015B2 (enExample)
EP (1) EP3275867B1 (enExample)
JP (1) JP6449482B2 (enExample)
KR (1) KR102087918B1 (enExample)
CN (3) CN108516958B (enExample)
AU (1) AU2016236669B2 (enExample)
CA (1) CA2980484C (enExample)
IL (1) IL254098B (enExample)
MX (1) MX383376B (enExample)
NZ (1) NZ735044A (enExample)
RU (1) RU2683566C1 (enExample)
SG (1) SG11201706869XA (enExample)
TW (2) TWI666201B (enExample)
WO (1) WO2016150255A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108516958B (zh) 2015-03-24 2020-07-17 上海璎黎药业有限公司 稠环衍生物、其制备方法、中间体、药物组合物及应用
KR102591886B1 (ko) * 2015-07-21 2023-10-20 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. 축합고리 피리미딘계 화합물, 중간체, 이의 제조 방법, 조성물 및 응용
CN107286156A (zh) * 2016-04-05 2017-10-24 江苏新元素医药科技有限公司 新型urat1抑制剂及其在医药上的应用
CA3025078C (en) * 2016-05-23 2021-04-13 Cstone Pharmaceutical (Suzhou) Co., Ltd. Thiophene, manufacturing method thereof, and pharmaceutical application of same
CN106146533B (zh) * 2016-07-14 2018-04-03 华润赛科药业有限责任公司 含硫杂环羧酸类衍生物、其制备方法和应用
CN106083847B (zh) * 2016-08-03 2018-10-30 山东大学 一种咪唑并吡啶巯乙酸类衍生物及其制备方法与应用
CN108084186B (zh) * 2016-11-16 2021-06-25 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
WO2018090921A1 (zh) * 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
CN108033909A (zh) * 2017-12-20 2018-05-15 北京六合宁远科技有限公司 一种6-甲基-4-溴-异喹啉的制备方法
CN109608432B (zh) * 2018-12-17 2022-10-11 江苏艾立康医药科技有限公司 作为urat1抑制剂的噻吩类衍生物
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
CN111303161B (zh) * 2020-04-14 2021-01-05 遵义医科大学珠海校区 嘧啶并氮杂环类化合物及其用途
CN111763218B (zh) * 2020-07-14 2021-05-28 山东大学 一种噻吩并嘧啶酮巯乙酸类衍生物及其制备方法与应用
WO2023131017A1 (zh) 2022-01-04 2023-07-13 上海璎黎药业有限公司 一种稠环衍生物的晶型、其制备方法及其应用
CN116465985B (zh) * 2023-03-03 2024-12-10 连云港杰瑞药业有限公司 一种气相色谱法检测α-核糖甲磺酸酯中残留溶剂的方法
WO2024209363A1 (en) 2023-04-06 2024-10-10 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators
CN118955327A (zh) * 2024-06-26 2024-11-15 安徽大学 一种4-溴-1-萘甲腈的合成方法
CN118878551A (zh) * 2024-07-08 2024-11-01 安徽大学 一种4-溴噻吩并[2,3-c]吡啶-2-羧酸乙酯的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558655A (en) * 1969-06-25 1971-01-26 Parke Davis & Co Benzo(b)thiopheneacetic acid compounds
US4224330A (en) * 1979-09-13 1980-09-23 Zoecon Corporation Esters and thiolesters of benzothienyl acids
US20140005221A1 (en) * 2011-01-28 2014-01-02 Sato Pharmaceutical Co., Ltd. Ring-fused compound
CA2880178A1 (en) * 2012-07-27 2014-01-30 Sato Pharmaceutical Co., Ltd. Difluoromethylene compound
EP2762476A1 (en) * 2011-09-30 2014-08-06 Taiho Pharmaceutical Co., Ltd. 1,2,4-triazine-6-carboxamide derivative

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO282896A0 (en) 1996-10-07 1996-10-31 Fujisawa Pharmaceutical Co., Ltd. Novel compounds
ATE339406T1 (de) 1999-09-23 2006-10-15 Astrazeneca Ab Chinazoline verbindungen als heilmittel
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
TWI328009B (en) * 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
ATE370941T1 (de) * 2003-11-20 2007-09-15 Lilly Co Eli Modulatoren des vitamin-d-rezeptors
EP1697427B1 (en) * 2003-12-22 2008-12-24 Basell Polyolefine GmbH Metallocene compounds
SE0400440D0 (sv) * 2004-02-25 2004-02-25 Active Biotech Ab Novel Cinnamic Amides
GB0426313D0 (en) * 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
US8916550B2 (en) * 2005-05-09 2014-12-23 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
CN101360743A (zh) * 2006-01-30 2009-02-04 Irm责任有限公司 作为ppar调节剂的多环的1,2,3,4-四氢-异喹啉衍生物和包含它们的组合物
BRPI0708782A2 (pt) 2006-03-16 2011-06-14 Astellas Pharma Inc derivado de triazol ou um sal deste
US7960567B2 (en) * 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
CA2722606A1 (en) * 2008-05-05 2009-11-12 Amgen Inc. Urea compounds as gamma secretase modulators
US8809382B2 (en) * 2009-05-04 2014-08-19 The Royal Institution For The Advancement Of Learning/Mcgill University 5-oxo-ETE receptor antagonist compounds
TW201116281A (en) 2009-08-06 2011-05-16 Astellas Pharma Inc N atom containing ring acylguanidine derivatives
NZ705135A (en) * 2010-05-26 2017-10-27 Sunovion Pharmaceuticals Inc Heteroaryl compounds and methods of use thereof
WO2011159840A2 (en) * 2010-06-16 2011-12-22 Ardea Biosciences, Inc. Phenylthioacetate compounds, compositions and methods of use
US20140005224A1 (en) 2010-10-27 2014-01-02 Bayer Intellectual Property Gmbh Heteroaryl piperidine and heteroaryl piperazine derivatives as fungicides
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR093519A1 (es) * 2012-11-20 2015-06-10 Hoffmann La Roche 1,6-naftiridinas sustituidas
RU2673549C2 (ru) * 2013-05-03 2018-11-28 Ф. Хоффманн-Ля Рош Аг Производные изохинолина, стимулирующие нейрогенез
US9550770B2 (en) 2013-08-23 2017-01-24 Neupharma, Inc. Substituted quinazolines for inhibiting kinase activity
CN107567443B (zh) * 2014-12-24 2023-04-28 株式会社Lg化学 作为gpr120激动剂的联芳基衍生物
CN108516958B (zh) 2015-03-24 2020-07-17 上海璎黎药业有限公司 稠环衍生物、其制备方法、中间体、药物组合物及应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558655A (en) * 1969-06-25 1971-01-26 Parke Davis & Co Benzo(b)thiopheneacetic acid compounds
US4224330A (en) * 1979-09-13 1980-09-23 Zoecon Corporation Esters and thiolesters of benzothienyl acids
US20140005221A1 (en) * 2011-01-28 2014-01-02 Sato Pharmaceutical Co., Ltd. Ring-fused compound
EP2762476A1 (en) * 2011-09-30 2014-08-06 Taiho Pharmaceutical Co., Ltd. 1,2,4-triazine-6-carboxamide derivative
CA2880178A1 (en) * 2012-07-27 2014-01-30 Sato Pharmaceutical Co., Ltd. Difluoromethylene compound

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Developing Potent Human Uric Acid Transporter 1(hURAT1) Inhibitors;Michael F. Wempe, et al.;《J. Med. Chem.》;20110428;第54卷(第8期);第2701-2713页 *
H3O+催化苯并噻吩-2-甲酸脱羧反应;宋明芝, 等.;《计算机与应用化学》;20130928;第30卷(第9期);第1022页图1化合物R1 *
Intramolecular cyclization of amido acids into pyrrolidinothieno (or [1]benzothieno)[3]azepinediones;Mohamed Othman, et al.;《Journal of Heterocyclic Chemistry》;19970228;第34卷(第1期);第226页Scheme 1化合物4c *
尿酸转运蛋白功能的研究进展;李懋,等.;《医学综述》;20150131;第21卷(第1期);第32-34页 *

Also Published As

Publication number Publication date
CN108299425B (zh) 2020-09-18
SG11201706869XA (en) 2017-09-28
EP3275867A4 (en) 2018-01-31
TW201808909A (zh) 2018-03-16
RU2683566C1 (ru) 2019-03-29
EP3275867B1 (en) 2020-06-10
TWI666201B (zh) 2019-07-21
CN108299425A (zh) 2018-07-20
MX383376B (es) 2025-03-13
HK1226055A1 (zh) 2017-09-22
CN106008340A (zh) 2016-10-12
US20180265476A1 (en) 2018-09-20
JP2018509451A (ja) 2018-04-05
AU2016236669B2 (en) 2018-11-08
CA2980484C (en) 2019-11-26
TW201641491A (zh) 2016-12-01
TWI675026B (zh) 2019-10-21
KR20170123705A (ko) 2017-11-08
WO2016150255A1 (zh) 2016-09-29
KR102087918B1 (ko) 2020-03-12
MX2017012009A (es) 2018-06-06
US10100016B2 (en) 2018-10-16
CN108516958A (zh) 2018-09-11
IL254098B (en) 2020-03-31
US20180072678A1 (en) 2018-03-15
CA2980484A1 (en) 2016-09-29
JP6449482B2 (ja) 2019-01-09
IL254098A0 (en) 2017-10-31
AU2016236669A1 (en) 2017-09-21
EP3275867A1 (en) 2018-01-31
US10100015B2 (en) 2018-10-16
NZ735044A (en) 2018-10-26
CN108516958B (zh) 2020-07-17

Similar Documents

Publication Publication Date Title
CN106008340B (zh) 稠环衍生物、其制备方法、中间体、药物组合物及应用
CN105828820B (zh) 布罗莫结构域抑制剂
CN111440189B (zh) 稠环嘧啶氨基衍生物、其制备方法、中间体、药物组合物及应用
WO2021218755A1 (zh) Shp2抑制剂及其组合物和应用
CN106366093B (zh) 稠环嘧啶类化合物、中间体、其制备方法、组合物和应用
CN107531705A (zh) 双环酮磺酰胺化合物
WO2016169421A1 (zh) 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用
WO2023202623A1 (zh) Polq抑制剂化合物及其应用
CN112513041B (zh) 三环化合物
CN103304571B (zh) 螺环化合物、其制备方法、中间体、药物组合物和应用
HK1226055B (zh) 稠环衍生物、其制备方法、中间体、药物组合物及应用
WO2025252235A1 (zh) 一种用于调节β2整联蛋白的化合物及其药物组合物
WO2022253081A1 (zh) 氧化膦衍生物及其制备方法和应用
WO2024067463A1 (zh) 苯并[7]环烯类衍生物、包含其的药物组合物及其医药用途
HK40073781B (zh) 喹喔啉酮衍生物作为kras g12c突变蛋白的不可逆抑制剂
CN101379042A (zh) 作为gabaa受体调节剂的取代的噌啉衍生物及其合成方法
HK1230186B (zh) 稠环嘧啶氨基衍生物、其制备方法、中间体、药物组合物及应用
HK1234036A1 (en) Fused pyrimidine compound, intermediate, preparation method therefor, composition and use thereof
HK1230186A1 (en) Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
HK1170224A1 (zh) 有效作为黄嘌呤氧化酶抑制剂的新化合物、该化合物的制备方法和含有该化合物的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1226055

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant